ensovibep

designed ankyrin repeat protein (synthetic bivalent human albumin-binding) fusion protein with designed ankyrin repeat protein (synthetic trivalent severe acute respiratory syndrome coronavirus 2 spike glycoprotein receptor binding domain-binding)

Also Known As:

Networked: 7 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Related Diseases

1.	COVID-19 01/01/2023 - "In this open-label, first-in-patient study a single dose of either 225 mg (n = 6) or 600 mg (n = 6) of ensovibep was administered intravenously in outpatients with mild-to-moderate COVID-19 symptoms. " 01/01/2023 - "Viral clearance, pharmacokinetics and tolerability of ensovibep in patients with mild to moderate COVID-19: A phase 2a, open-label, single-dose escalation study." 01/01/2023 - "To assess viral clearance, pharmacokinetics, tolerability and symptom evolution following ensovibep administration in symptomatic COVID-19 outpatients. " 01/01/2023 - "Efficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19." 01/01/2023 - "Efficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19."
2.	Infections 01/01/2023 - "Ensovibep proved safe in this first-in-human safety study and exhibited PK and PD parameters consistent with the expected treatment period required for acute COVID-19 infection."

Related Drugs and Biologics

1.	Proteins (Proteins, Gene)
2.	Antiviral Agents (Antivirals)
3.	ensovibep
4.	Fluvoxamine (Luvox)
5.	Staphylococcal Protein A (Protein A)
6.	Arginine (L-Arginine)
7.	AT-511
8.	remdesivir

Related Therapies and Procedures

1.	Therapeutics
2.	Intravenous Administration